Following encouraging results during the first year of Selcia's integrated drug discovery collaboration with Parkinson’s UK, we are pleased to announce that the partnership will continue into a second year.  As part of this programme we are focussed in developing novel small molecules that have the ability to induce target genes that improve the symptoms and slow the progression of Parkinson’s.   

https://www.parkinsonsvirtualbiotech.co.uk/single-post/2019/01/31/Parkinson%E2%80%99s-UK-invests-further-%C2%A315million-to-develop-novel-gene-transcription-modulators